GlassScriptPhysician profile
Jane L Rohrer
NPI 1659347953
$789.08
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $115 · 2021: $11.22 · 2023: $62.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.63 | 2019-2023 | Ubrelvy |
| Daiichi Sankyo INC. | $94.24 | 2019-2020 | |
| Therapeuticsmd, INC. | $71.99 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.39 | 2019 | |
| Allergan, INC. | $53.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.98 | 2019 | |
| Amgen INC. | $24.41 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.35 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $21.14 | 2019 | |
| Lupin INC. | $20.86 | 2019 | |
| Becton, Dickinson and Company | $16.14 | 2019 | |
| Astellas Pharma US INC | $14.62 | 2019 | |
| Aspira Women'S Health INC | $14.62 | 2020 | |
| Coopersurgical, INC. | $13.54 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $11.87 | 2019 | |
| Avion Pharmaceuticals | $11.52 | 2019 | |
| Mylan Pharmaceuticals INC. | $10.96 | 2019 | |
| Vivus LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Rohrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.